P.3.c.064 Interventions in antipsychotics-treated patients with cardiometabolic risk factors or metabolic syndrome

Larsen, Jens Rolighed; Holdrup, Mette; Christensen, Birgitte Mønster; Sigalin, Catarina; Nilsson, Peter; Kolb, Stephen J.

doi:10.1016/s0924-977x(08)70648-5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though three months seemingly were too short to retrieve statistically sound evidence on all possible risk factors, we observed an early increase of triglyceride levels. Our results once more emphasize how important the controlling of the patients' metabolic situation is in schizophrenia therapy [ 37 , 38 ] irrespective of antipsychotic medication.…”

Section: Discussionmentioning

confidence: 64%

Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

et al. 2011

View full text Add to dashboard Cite

BackgroundThis observational study explored the prevalence of metabolic syndrome (MetS) in adult in- and outpatients with untreated or treated schizophrenia at baseline, and month-3 after initiation or switch of antipsychotic treatment.MethodsMetS-prevalence (AHA/NHLB-definition) was assessed and Clopper-Pearson 95% confidence intervals (CIs) were calculated. Factors associated with MetS were explored through univariate and multivariate logistic regressions (both visits).ResultsMetS-prevalence was 44.3% (CI 39.8;48.9) at baseline and 49.6% (CI 45.0;54.2) at month-3. Previously unmedicated patients showed the lowest baseline MetS-prevalence (24.7%, CI 18.3;32.1). MetS-prevalence was not significantly different, regardless if patients previously received typical or atypical antipsychotics. Increased MetS-risk was associated with somatic comorbidity and non-smoking at both visits, and with non-psychiatric co-medication, male sex, and increased C-reactive protein at month-3.ConclusionsAt baseline, MetS was most prevalent in patients with previous antipsychotic medication. Limited metabolic changes were observed 3 months after switch/initiation of antipsychotic therapy.Trial Registration NumberClinicalTrials.gov Identifier: n.a.

show abstract

Section: Discussionmentioning

confidence: 64%